Price
Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.
Smart Score
AverageHaemonetics is a global medical technology company dedicated to improving the quality, effectiveness and efficiency of health care. Our innovative solutions addressing critical medical needs include a suite of hospital technologies designed to advance standards of care and help enhance outcomes for patients; end-to-end plasma collection technologies to optimize operations for plasma centers; and products to enable blood centers to collect in-demand blood components.
In the company’s own words · 10-K filed May 20, 2026 · SEC EDGAR
Business segments
Q4 2025 · $339.0MThe company’s own SEC segment disclosure.
- Plasma$138.9M41%
- Hemostasis Management Hospital$87.4M26%
- Blood Center$56.6M17%
- Interventional Technologies Hospital$56.1M17%
Haemonetics Corporation (HAE) reported revenue of $346M in Q4 2026 (quarter ended March 28, 2026), up 4.8% from the same quarter a year earlier. That came with a gross margin of 57% and net loss of $20M. For the full year FY2026, revenue was $1.33B (−2.0% year on year) and net income $97M. Its largest segment in 2025-Q4 was Plasma at $139M, 41% of the disclosed total, just ahead of Hemostasis Management Hospital at 26%.
Raw charts
11 series · TTMAs reported to the SEC, without any scoring.